Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:intradigm [2023/03/04 21:22] liam | pharmaceutical_companies:intradigm [2024/11/09 19:40] (current) liam [External links] |
---|
===== History ===== | ===== History ===== |
| |
Intradigm was founded in mid-2000 by [[:Jill Glasspool-Malone]], [[:Jim Mixson]] and [[:Martin Woodle]].((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company's non-viral gene delivery technology was originally developed by [[Genetic Therepies Inc.]] (GTI) and licensed to Intradigm by [[Novartis]] after their several attempts at [[:gene therapy]] failed.((Kirchweger, G. (2003). //Genetic Therapies Inc.: tight-lipped for now.// Molecular Therapy, 7(3), 293. https://doi.org/10.1016/s1525-0016(03)00051-0)) The license agreement was transferred to Intradigm contingent on funding from [[:Emerging Technology Partners]] and Novartis’ own venture fund. | Intradigm was founded in mid-2000 by [[:Jill Glasspool-Malone]], [[:Jim Mixson]] and [[:Martin Woodle]].((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company's non-viral gene delivery technology was originally developed by [[Genetic Therapies, Inc.]] (GTI) and licensed to Intradigm by [[Novartis]] after their several attempts at [[:gene therapy]] failed.((Kirchweger, G. (2003). //Genetic Therapies Inc.: tight-lipped for now.// Molecular Therapy, 7(3), 293. https://doi.org/10.1016/s1525-0016(03)00051-0)) The license agreement was transferred to Intradigm contingent on funding from [[:Emerging Technology Partners]] and Novartis’ own venture fund. |
| |
| {{ :pharmaceutical_companies:2002-11-28-the-baltimore-sun-pg-c2-clip-novavax-ceo.jpg?300|}} |
| |
Glasspool-Malone began working on the startup in August 1999 as Managing Director, helping to secure $2.3 million in venture capital funding, setting up laboratory and office facilities, and developing the company's scientific and business development plan.((//Jill Glasspool Malone.// ResearchGate. Retrieved March 4, 2023, from https://archive.ph/Z5Pgx)) Intradigm entered the [[:united_states:Maryland|State of Maryland]]'s Challenge Investment Fund program on September 20, 2000. | Glasspool-Malone began working on the startup in August 1999 as Managing Director, helping to secure $2.3 million in venture capital funding, setting up laboratory and office facilities, and developing the company's scientific and business development plan.((//Jill Glasspool Malone.// ResearchGate. Retrieved March 4, 2023, from https://archive.ph/Z5Pgx)) Intradigm entered the [[:united_states:Maryland|State of Maryland]]'s Challenge Investment Fund program on September 20, 2000. |
| |
Intradigm closed its Series A round of funding in June 2001, receiving a $300,000 investment from the [[:Maryland Venture Fund]] (MVF).((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company "entered in to a multi-year, multi-product development program" with [[DirectGene]] in December 2001 to "jointly develop products aimed at prostate and pancreatic cancer."((//Collaborations.// DirectGene. Retrieved August 26, 2002, from https://archive.ph/GW4U5)) | Intradigm closed its Series A round of funding in June 2001, receiving a $300,000 investment from the [[:Maryland Venture Fund]] (MVF).((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company "entered in to a multi-year, multi-product development program" with [[DirectGene]] in December 2001 to "jointly develop products aimed at prostate and pancreatic cancer."((//Collaborations.// DirectGene. Retrieved August 26, 2002, from https://archive.ph/GW4U5)) |
| |
{{ :pharmaceutical_companies:2002-11-28-the-baltimore-sun-pg-c2-clip-novavax-ceo.jpg?400|}} | |
| |
On November 22, 2002, Itradigm announced it had hired former [[Novavax]] CEO [[:John Spears]] as its Chairman and CEO.((//Ex-chief of Novavax hired as Intradigm CEO.// (2002, November 28). The Baltimore Sun, C2. https://www.newspapers.com/image/248431447/?terms=Intradigm&match=1)) ((//Intradigm appoints John A. Spears Chairman and CEO.// (2002, December 2). PharmaBiz. https://archive.ph/oRzIK)) | On November 22, 2002, Itradigm announced it had hired former [[Novavax]] CEO [[:John Spears]] as its Chairman and CEO.((//Ex-chief of Novavax hired as Intradigm CEO.// (2002, November 28). The Baltimore Sun, C2. https://www.newspapers.com/image/248431447/?terms=Intradigm&match=1)) ((//Intradigm appoints John A. Spears Chairman and CEO.// (2002, December 2). PharmaBiz. https://archive.ph/oRzIK)) |
| |
| On December 16, 2009, Intradigm was acquired by [[Silence Therapeutics]].((//Intradigm Corporation - Crunchbase Company Profile & Funding.// Crunchbase. Retrieved March 5, 2023, from https://www.crunchbase.com/organization/intradigm-corporation)) |
| |
===== Organization ===== | ===== Organization ===== |
==== Funding ==== | ==== Funding ==== |
| |
Investors in Intradigm include:((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) | Investors in Intradigm include:((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) ((//Intradigm Corporation - Funding, Financials, Valuation & Investors.// Crunchbase. Retrieved March 5, 2023, from https://crunchbase.com/organization/intradigm-corporation/company_financials)) |
| |
| * [[:Alta Partners]] |
| * [[:Astellas Venture Management]] |
| * [[Eli Lilly]] |
* [[:Emerging Technology Parters]] | * [[:Emerging Technology Parters]] |
| * [[:Frazier Healthcare Partners]] |
* [[:Maryland Venture Fund]] | * [[:Maryland Venture Fund]] |
| * [[:MediBIC Group]] |
| * [[:MP Healthcare Venture Management]] |
* [[:Novartis Venture Fund]] | * [[:Novartis Venture Fund]] |
| * [[:Roche Venture Fund]] |
==== Personnel ==== | ==== Personnel ==== |
| |
^ Board of Directors ^^^ | ^ Board of Directors ^^^ |
| [[:Robert Riley]] | Director | - | | | [[:Robert Riley]] | Director | - | |
| ^ Scientific Advisory Board((//About Us.// Interdigm Corporation. Retrieved May 10, 2002, from https://archive.ph/pOX3Y)) ^^^ |
| | [[:Paul Tolstoshev]] | Member | Formerly Vice President of Research at [[Genetic Therapies, Inc.]] | |
| | [[:Anton Wellstein]] | Member | [[:Georgetown University]] | |
| | [[:Richard Heller]] | Member | [[:University of South Florida]] | |
| | [[:Richard Gilbert]] | Member | [[:University of South Florida]] | |
| | [[:Gert Storm]] | Member | [[:Utrecht University]] | |
| | [[:Bruce Trapnell]] | Member | [[:University of Cincinnati]], formerly VP for Virology of [[Genetic Therapies, Inc.]] | |
| | [[:Dexi Liu]] | Member | [[:University of Pittsburgh]] | |
| | [[:Joel Cohen]] | Member | [[:University of the Pacific]] | |
| | [[:Joel Jessee]] | Member | Vice President of [[Atto Bioscience]] | |
| | [[:Hamid Ghandehari]] | Member | [[:University of Maryland at Baltimore]] | |
| | [[:Archibald James Mixson]] | Member | [[:University of Maryland at Baltimore]] | |
| |
===== External links ===== | ===== External links ===== |
| |
| * [[https://wiki.whiteroseintelligence.com/en/Intradigm|Campfire Wiki]] |
* [[https://sites.google.com/housatonicits.com/home0004/research/intradigm-corp|Housatonic]] | * [[https://sites.google.com/housatonicits.com/home0004/research/intradigm-corp|Housatonic]] |